Nothing Special   »   [go: up one dir, main page]

Redondo-García et al., 2023 - Google Patents

Human leukocyte immunoglobulin-like receptors in health and disease

Redondo-García et al., 2023

View HTML
Document ID
13495036625834775781
Author
Redondo-García S
Barritt C
Papagregoriou C
Yeboah M
Frendeus B
Cragg M
Roghanian A
Publication year
Publication venue
Frontiers in Immunology

External Links

Snippet

Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Dawson et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells
Xu-Monette et al. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response?
Li et al. Tumor immunotherapy: new aspects of natural killer cells
Kim et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T-and B-cell responses
Francisco et al. The PD‐1 pathway in tolerance and autoimmunity
Nausch et al. NKG2D ligands in tumor immunity
Geller et al. Use of allogeneic NK cells for cancer immunotherapy
JP2021177771A (en) Cs1-specific chimeric antigen receptor-engineered immune effector cell
Gorczynski CD200: CD200R‐mediated regulation of immunity
Anderson et al. Regulation of T‐cell immunity by leucocyte immunoglobulin‐like receptors: innate immune receptors for self on antigen‐presenting cells
Abdallah et al. Leukocyte immunoglobulin-like receptors in regulating the immune response in infectious diseases: A window of opportunity to pathogen persistence and a sound target in therapeutics
CN109790213B (en) Methods for identifying LILRB blocking antibodies
JP7515209B2 (en) MR1-restricted T-cell receptor for cancer immunotherapy
Adair et al. Human Tregs made antigen specific by gene modification: the power to treat autoimmunity and antidrug antibodies with precision
JP2019525898A (en) Human leukocyte antigen-restricted gamma delta T cell receptor and method of use thereof
Redondo-García et al. Human leukocyte immunoglobulin-like receptors in health and disease
Chruscinski et al. Role of regulatory T cells (Treg) and the Treg effector molecule fibrinogen-like protein 2 in alloimmunity and autoimmunity
Gámez-Díaz et al. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
Mason et al. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
Hartigan et al. Memory T‐cell exhaustion and tolerance in transplantation
De Louche et al. Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy
CN117355327A (en) CAR NKT expressing SHRNA embedded in artificial microRNAs for down-regulating MHC class I and class II expression
Modak et al. Engagement of distinct epitopes on CD 43 induces different co‐stimulatory pathways in human T cells
CN118055944A (en) Modulating Bcl-2 enhances efficacy of chimeric antigen receptor cancer immunotherapy
US20240360236A1 (en) Methods for targeted immunotherapy of acute myeloid leukemia (aml)